New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
ORCHID Trial of Olaparib Monotherapy Could Lay Groundwork for Investigating PARP Inhibitors in Advanced RCC

ORCHID Trial of Olaparib Monotherapy Could Lay Groundwork for Investigating PARP Inhibitors in Advanced RCC

August 11, 2023Megan HollaschYasser Mohamed Ali Ged, MBBS, highlights the early efficacy seen in patients with renal cell carcinoma with BAP1 mutations and next steps for the ORCHID trial.Yasser Moham
World medicine November 24,2023
ORCHID Trial of Olaparib Monotherapy Could Lay Groundwork for Investigating PARP Inhibitors in Advanced RCC

ORCHID Trial of Olaparib Monotherapy Could Lay Groundwork for Investigating PARP Inhibitors in Advanced RCC

August 11, 2023Megan HollaschYasser Mohamed Ali Ged, MBBS, highlights the early efficacy seen in patients with renal cell carcinoma with BAP1 mutations and next steps for the ORCHID trial.Yasser Moham
World medicine November 24,2023
NKX019 Showcases Manageable Safety, Early Activity in R/R B-cell Non-Hodgkin Lymphoma

NKX019 Showcases Manageable Safety, Early Activity in R/R B-cell Non-Hodgkin Lymphoma

July 27, 2023Kristi RosaThe allogeneic natural killer cell therapy NKX019 was found to have an acceptable toxicity profile and to induce deep and durable responses in patients with relapsed or refract
World medicine November 24,2023
NKX019 Showcases Manageable Safety, Early Activity in R/R B-cell Non-Hodgkin Lymphoma

NKX019 Showcases Manageable Safety, Early Activity in R/R B-cell Non-Hodgkin Lymphoma

July 27, 2023Kristi RosaThe allogeneic natural killer cell therapy NKX019 was found to have an acceptable toxicity profile and to induce deep and durable responses in patients with relapsed or refract
World medicine November 24,2023
Tumor-immune interactions predict treatment responses in multiple myeloma

Tumor-immune interactions predict treatment responses in multiple myeloma

Nov 9 2023Sylvester Comprehensive Cancer CenterA multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactio
World medicine November 24,2023
Tumor-immune interactions predict treatment responses in multiple myeloma

Tumor-immune interactions predict treatment responses in multiple myeloma

Nov 9 2023Sylvester Comprehensive Cancer CenterA multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactio
World medicine November 24,2023
Linvoseltamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

Linvoseltamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

August 10, 2023Ashling WahnerHans Lee, MD,discusses unmet needs in patients with relapsed/refractory multiple myeloma, highlights key efficacy and safety findings from the LINKER-MM1 trial, and
World medicine November 24,2023
Linvoseltamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

Linvoseltamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

August 10, 2023Ashling WahnerHans Lee, MD,discusses unmet needs in patients with relapsed/refractory multiple myeloma, highlights key efficacy and safety findings from the LINKER-MM1 trial, and
World medicine November 24,2023
Combined application of therapeutic viruses and nanomaterials to revolutionize cancer therapy

Combined application of therapeutic viruses and nanomaterials to revolutionize cancer therapy

ByNeha MathurNov 22 2023Reviewed byLily Ramsey, LLMIn a recent article published inMolecules, researchers discuss using oncolytic viruses (OVs) in combination with nanomaterials as a
World medicine November 24,2023
Combined application of therapeutic viruses and nanomaterials to revolutionize cancer therapy

Combined application of therapeutic viruses and nanomaterials to revolutionize cancer therapy

ByNeha MathurNov 22 2023Reviewed byLily Ramsey, LLMIn a recent article published inMolecules, researchers discuss using oncolytic viruses (OVs) in combination with nanomaterials as a
World medicine November 24,2023
GVAX Cancer Vaccine Plus Nivolumab and Urelumab Elicits Early Efficacy in Pancreatic Adenocarcinoma

GVAX Cancer Vaccine Plus Nivolumab and Urelumab Elicits Early Efficacy in Pancreatic Adenocarcinoma

August 14, 2023Kyle DohertyTreatment with the GVAX pancreatic cancer vaccine plus nivolumab and urelumab increased the presence of intratumoral activated cytotoxic T cells and showed early signs of ef
World medicine November 24,2023
GVAX Cancer Vaccine Plus Nivolumab and Urelumab Elicits Early Efficacy in Pancreatic Adenocarcinoma

GVAX Cancer Vaccine Plus Nivolumab and Urelumab Elicits Early Efficacy in Pancreatic Adenocarcinoma

August 14, 2023Kyle DohertyTreatment with the GVAX pancreatic cancer vaccine plus nivolumab and urelumab increased the presence of intratumoral activated cytotoxic T cells and showed early signs of ef
World medicine November 24,2023
Drug for children with achondroplasia may help reduce chances of SIDS

Drug for children with achondroplasia may help reduce chances of SIDS

Nov 21 2023Murdoch Childrens Research InstituteA drug that boosts bone growth in children with the most common form of dwarfism, may also reduce their chances of sudden infant death syndrome, sleep ap
World medicine November 24,2023
Drug for children with achondroplasia may help reduce chances of SIDS

Drug for children with achondroplasia may help reduce chances of SIDS

Nov 21 2023Murdoch Childrens Research InstituteA drug that boosts bone growth in children with the most common form of dwarfism, may also reduce their chances of sudden infant death syndrome, sleep ap
World medicine November 24,2023
Sex-specific brain immunometabolism differences may underlie increased Alzheimer's risk in women

Sex-specific brain immunometabolism differences may underlie increased Alzheimer's risk in women

Nov 21 2023Cleveland ClinicCleveland Clinic researchers analyzed genes and brain tissue of patients with Alzheimer's and found that differences in brain immunometabolism – the interactions between
World medicine November 24,2023
Sex-specific brain immunometabolism differences may underlie increased Alzheimer's risk in women

Sex-specific brain immunometabolism differences may underlie increased Alzheimer's risk in women

Nov 21 2023Cleveland ClinicCleveland Clinic researchers analyzed genes and brain tissue of patients with Alzheimer's and found that differences in brain immunometabolism – the interactions between
World medicine November 24,2023
Anti-rheumatic drugs could have a preventive effect on autoimmunethyroid disease

Anti-rheumatic drugs could have a preventive effect on autoimmunethyroid disease

Nov 22 2023Karolinska InstitutetAnti-rheumatic drugs used for rheumatoid arthritis might prevent the development of autoimmune thyroid disease, according to a new observational study by research
World medicine November 24,2023
Anti-rheumatic drugs could have a preventive effect on autoimmunethyroid disease

Anti-rheumatic drugs could have a preventive effect on autoimmunethyroid disease

Nov 22 2023Karolinska InstitutetAnti-rheumatic drugs used for rheumatoid arthritis might prevent the development of autoimmune thyroid disease, according to a new observational study by research
World medicine November 24,2023
Reducing cholesterol esters protects the brain againstAlzheimer's-likedamage

Reducing cholesterol esters protects the brain againstAlzheimer's-likedamage

Nov 22 2023Washington University School of MedicineIn Alzheimer's disease and related dementias, cognitive decline is driven by the overaccumulation of a normal brain protein known as tau. Whereve
World medicine November 24,2023
Reducing cholesterol esters protects the brain againstAlzheimer's-likedamage

Reducing cholesterol esters protects the brain againstAlzheimer's-likedamage

Nov 22 2023Washington University School of MedicineIn Alzheimer's disease and related dementias, cognitive decline is driven by the overaccumulation of a normal brain protein known as tau. Whereve
World medicine November 24,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com